Report ID : 1290846 | Published : February 2025 | Study Period : 2023-2033 | Format : PDF + Excel
The market size of the Anti-Fungal Agents Industry is categorized based on Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, Others) and Route of Administration (Oral, Topical, Injectable, Others) and Indication (Candidiasis, Aspergillosis, Dermatophytosis, Cryptococcosis, Others) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).
In 2023, the size of the Anti-Fungal Agents Industry was valued at $14.5 billion and is anticipated to reach $24.2 billion by 2033, expanding at a 5.3% CAGR between 2024 and 2033. The report encompasses multiple segments and provides an analysis of significant trends and factors impacting the market.
The anti-fungal agents market is growing significantly due to people being more aware of the health implications of fungal infections. There is a rise in immunocompromised patients undergoing chemotherapy or living with HIV/AIDS which heavily contributes to the demand. With the advancement in medical science, the market is able to currently offer topical treatments, systemic medications, and other emerging therapies. All of these products are aimed to help defeat and reduce the risk of public health crises from fungal pathogens. The market is now a staple in the pharmaceutical industry.
The global focus of public health is a progression and management of an infectious disease, so the anti-fungal agents market has great potential growth. The researchers and pharmaceutical companies are targeting innovation and new formulations to resolve the issues of drug resistance and devise multi-targeted therapies for specific fungal species. The escalating rates of chronic ailments and fungal infections in health care settings also support the continuous R&D efforts in the sector. In order to understand the microeconomics of anti-fungal agents market most important drivers, challenges, and opportunities have to be analyzed as they play a central role in the future of the market.
ATTRIBUTES | DETAILS |
---|---|
STUDY PERIOD | 2023-2033 |
BASE YEAR | 2023 |
FORECAST PERIOD | 2024-2033 |
HISTORICAL PERIOD | 2023-2024 |
UNIT | VALUE (USD BILLION) |
KEY COMPANIES PROFILED | Pfizer Inc., Bristol-Myers Squibb Company, Merck & Co. Inc., Gilead Sciences Inc., Novartis AG, Bayer AG, AbbVie Inc., F. Hoffmann-La Roche Ltd, Johnson & Johnson, Astellas Pharma Inc., Mylan N.V. |
SEGMENTS COVERED |
By Drug Class - Azoles, Echinocandins, Polyenes, Allylamines, Others By Route of Administration - Oral, Topical, Injectable, Others By Indication - Candidiasis, Aspergillosis, Dermatophytosis, Cryptococcosis, Others By Geography - North America, Europe, APAC, Middle East Asia & Rest of World. |
The Anti-Fungal Agents Industry is undergoing significant changes due to various dynamic factors. This section delves into the key drivers, restraints, opportunities, and challenges that are shaping the market landscape.
This report provides an in-depth analysis of both established and rising industry participants. It provides broad lists of important companies organized by the types of products they offer and other market-related factors. In addition to characterizing these companies, the report contains the year each player entered the market, which is useful for research analysis by the study's analysts.
Verified Industry Insights offers one of the following report customization options to our respectable clients :
● Detailed profiling of additional market players (up to three players)
● SWOT analysis of key players (up to three players)
● Benchmarking of key players on the following parameters : Product portfolio, geographical reach, regional presence, and strategic alliances.
Verified Industry Insights offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to [email protected] or call us at +1 743 222 5439
© 2024 Verified Industry Insights. All Rights Reserved